// App-Quantinova.ai

EP783 : PHASE 2 STUDY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA STUDY)

Researchers

Presenter

  • Stephen Opat

Principal Investigators

  • Kim Linton

  • Pamela McKay

  • Bei Hu

  • Henry Chan

  • Jie Jin

  • Magdalena Sobieraj-Teague

  • Pier Luigi Zinzani

  • Morton Coleman

  • Peter Browett

  • Xiaoyan Ke

  • Mingyuan Sun

  • Robert Marcus

  • Craig Portell

  • Catherine Thieblemont

  • Kirit Ardeshna

  • Fontanet Bijou

  • Patricia Walker

  • Eliza Hawkes

  • Sally Mapp

  • Shir-Jing Ho

  • Melannie Co

  • Xiaotong Li

  • Wenxiao Zhou

  • Massimo Cappellini

  • Chris Tankersley

  • Jane Huang

  • Judith Trotman

Medical Centers

  • APHP, Hôpital Saint-Louis, Hemato-oncology, Paris University Diderot, Paris, France

  • Department of Haematology, Concord Hospital, Sydney, Australia

  • Flinders Medical Centre, Bedford Park, Australia

  • Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College,Tianjin,Chine

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Eastern Health, Box Hill Hospital, Victoria, Australia

  • Institute of Hematology an

  • Monash Health, Clayton, Australia

  • University of Melbourne, Melbourne, Australia

  • BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc.,San Mateo, CA,Vereinigte Staaten

  • NIHR Biomedical Research Centre at GOSH, London, United Kingdom

  • North Shore Hosp, Auckland, New Zealand

  • Grande Ospedale Metropolitano Niguarda, Milan, Italy

  • Institut Bergonie, Bordeaux, France

  • Department of Haematology,Princess Alexandra Hospital, Brisbane, Australia and Faculty of Medicine, University of Queensland,Brisbane,Australia

  • Concord Repatriation General Hospital, University of Sydney, Sydney, Australia

  • Clinical Research Alliance,Lake Success,United States

  • Department of Haematology,University College London Hospitals NHS Foundation Trust,London,Regno Unito

  • Levine Cancer Institute/Atrium Health,Charlotte,Verenigde Staten

  • Auckland City Hospital,Grafton,Nieuw Zeeland

  • Sarah Cannon Research Institute, London, United Kingdom

  • Peninsula Private Hospital, Frankston Victoria, Australia

  • Clinical Haematology Unit,Monash University,Clayton, Victoria,Australia

  • The Christie Hospital, Manchester, United Kingdom

  • Peking University Third Hospital Beijing China

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • University of Virginia Health System, Charlottesville, United States

  • Olivia Newton-John Cancer Research Institute/ Austin Health, Heidelberg, Australia

  • First Affiliated Hospital of Chengdu University, Chengdu, China

Locations

  • France

  • Australia

  • China

  • United Kingdom

  • United States

  • New Zealand

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mucosa-associated lymphoid tissue lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Ibrutinib

  • BGB-3111

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved